The Dark Horse of Precision Oncology: Why Guardant Health's Rise is Worth Watching Guardant Health, Inc. , a precision oncology firm, has flown under the radar despite its impressive growth trajectory.
Its innovative liquid biopsy technology has revolutionized cancer diagnosis and treatment, making it a compelling story for investors.
Artisan Mid Cap Fund's second quarter 2026 investor letter highlighted Guardant Health as one of the fund's top picks, citing its leadership in liquid biopsy diagnostics and expanding portfolio across oncology and cancer screening.